Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL286919 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL286918 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL8318136 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL7325420 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL14486114 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL8318140 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL14486115 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL28219869 | 0.96 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL28837862 | 0.92 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Asparagine SCHEMBL9395845 | 0.92 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | HYSLINK THERAPEUTICS (CN) | 2024-07-18 | — | — | US | claimed |
| WO-2024140917-A1 | ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海盛迪医药有限公司 | 2024-07-04 | — | — | WO | claimed |
| EP-4374879-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-04-02 | — | — | US | claimed |
| EP-4331613-A1 | PREPARATION METHOD FOR ANTIBODY-DRUG CONJUGATE, AND APPLICATION | Hyslink Therapeutics (CN) | 2024-03-06 | — | — | EP | claimed |
| EP-4331611-A1 | PREPARATION METHOD AND APPLICATION OF ANTIBODY DRUG CONJUGATE | Hyslink Therapeutics (CN) | 2024-03-06 | — | — | EP | claimed |
| EP-4331612-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | Hyslink Therapeutics (CN) | 2024-03-06 | — | — | EP | claimed |
| EP-4331616-A1 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Tsinghua University (CN) | 2024-03-06 | — | — | EP | claimed |
| WO-2024040075-A1 | EXTRACELLULAR VESICLE COMPRISING A BIOLOGICALLY ACTIVE MOLECULE AND A DUAL CLEAVABLE LINKER | LONZA SALES AG (CH) | 2024-02-22 | — | — | WO | claimed |
| WO-2024040076-A1 | EXTRACELLULAR VESICLE COMPRISING A BIOLOGICALLY ACTIVE MOLECULE AND A CELL PENETRATNG PEPTIDE CLEAVABLE LINKER | LONZA SALES AG (CH) | 2024-02-22 | — | — | WO | claimed |
| US-20210299269-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-09-30 | — | — | US | claimed |
| WO-2021123506-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-06-24 | — | — | WO | claimed |
| EP-3824909-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2021-05-26 | — | — | EP | claimed |
| EP-3801632-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2021-04-14 | — | — | EP | claimed |
| WO-2019232449-A9 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-24 | — | — | WO | claimed |
| WO-2020123836-A2 | HERBOXIDIENE SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-18 | — | — | WO | claimed |
| US-10428114-B2 | Type polypeptide targeting tumours | SICHUAN UNIVERSITY (CN) | 2019-10-01 | — | — | US | claimed |
| EP-3423105-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2019-01-09 | — | — | EP | claimed |
| US-20180298059-A1 | A NEW TYPE POLYPEPTIDE TARGETING TUMOURS | SICHUAN UNIVERSITY (CN) | 2018-10-18 | — | — | US | claimed |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MORPHOTEK, INC. | 2017-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | SLC7A5 4675/4885SLC1A3 3822/4885SLC1A2 4354/4885 |
| US-20210299269-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | SLC7A5 4675/4885SLC1A3 3822/4885SLC1A2 4354/4885 |
| US-10428114-B2 | Type polypeptide targeting tumours | APLNR, ARGLU1, ANPEP | SLC7A5 411/4885SLC1A3 273/4885SLC1A2 534/4885 |
| US-20180298059-A1 | A NEW TYPE POLYPEPTIDE TARGETING TUMOURS | APLNR, ARGLU1, ANPEP | SLC7A5 261/4885SLC1A3 270/4885SLC1A2 439/4885 |
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | SI, MET, MTX1 | SLC7A5 607/4885SLC1A3 589/4885SLC1A2 1360/4885 |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | SLC7A5 1383/4885SLC1A3 1580/4885SLC1A2 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.